Showing results (31-40 of 89) with videos related to
Sort By:
Pageof 9
Cancer|January 12, 2013
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapyFrank A Sinicrope, Nathan R Foster, Greg Yothers, et al.Oncology|December 16, 2014
A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patientsAminah Jatoi, Carmen Radecki Breitkopf, Nathan R Foster, et al.Lung Cancer (Amsterdam, Netherlands)|June 25, 2014
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621Julian R Molina, Nathan R Foster, Thanyanan Reungwetwattana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trialSteven R Alberts, Mark Schroeder, Charles Erlichman, et al.The Oncologist|January 26, 2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)Thorvardur R Halfdanarson, Nathan R Foster, George P Kim, et al.International Journal of Oncology|February 4, 2010
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trialsAminah Jatoi, Nathan R Foster, James R Egner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 27, 2010
Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumorsAminah Jatoi, Gamini Soori, Nathan R Foster, et al.Plos One|July 21, 2012
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trialShernan G Holtan, Preston D Steen, Nathan R Foster, et al.Cancer|October 21, 2010
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trialsNathan R Foster, Yingwei Qi, Qian Shi, et al.American Journal of Clinical Oncology|October 9, 2007
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)Aminah Jatoi, James A Martenson, Nathan R Foster, et al.Pageof 9